Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 68.20% | 66.92% | 27.12% | 24.49% | 6.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.20% | 66.92% | 27.12% | 24.49% | 6.11% |
| Cost of Revenue | -20.77% | -0.61% | 8.23% | 14.40% | 14.59% |
| Gross Profit | 210.21% | 161.99% | 52.95% | 38.05% | -5.11% |
| SG&A Expenses | 3.11% | 6.47% | 10.69% | 9.71% | 4.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.53% | 3.98% | 9.82% | 11.35% | 7.67% |
| Operating Income | 110.91% | 91.51% | 17.62% | 9.37% | -9.98% |
| Income Before Tax | 383.17% | 389.70% | 216.09% | 204.85% | -30.02% |
| Income Tax Expenses | 124.12% | 97.83% | 105.46% | 263.96% | 31.68% |
| Earnings from Continuing Operations | 296.36% | 287.70% | 159.40% | 128.54% | -30.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 296.36% | 287.70% | 159.40% | 128.54% | -30.30% |
| EBIT | 110.91% | 91.51% | 17.62% | 9.37% | -9.98% |
| EBITDA | 114.95% | 95.15% | 18.32% | 9.76% | -12.66% |
| EPS Basic | 291.21% | 281.11% | 156.96% | 126.61% | -37.81% |
| Normalized Basic EPS | 136.24% | 111.39% | 224.97% | 213.79% | -27.49% |
| EPS Diluted | 285.86% | 275.63% | 155.43% | 125.08% | -38.04% |
| Normalized Diluted EPS | 139.38% | 114.80% | 223.07% | 211.61% | -27.49% |
| Average Basic Shares Outstanding | 3.07% | 3.02% | 2.16% | -0.29% | -4.81% |
| Average Diluted Shares Outstanding | 5.17% | 5.13% | 3.15% | -0.02% | -4.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |